Germany · Delayed Price · Currency is EUR Catalyst Pharmaceuticals Company Description
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States.
It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor that is used to treat focal onset seizures, as well as tonic-clonic seizures; Ruzurgi for the treatment of pediatric LEMS patients; and AGAMREE, a corticosteroid for the treatment of duchenne muscular dystrophy.
The company has license agreements with BioMarin Pharmaceutical Inc.; and a collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets.
Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
| Country | United States |
| Founded | 2002 |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 181 |
| CEO | Richard John Daly |
Contact Details
Address: 355 Alhambra Circle Coral Gables, Delaware 33134 United States | |
| Phone | 305 420 3200 |
| Website | catalystpharma.com |
Stock Details
| Ticker Symbol | CN2 |
| Exchange | Frankfurt Stock Exchange |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Richard John Daly | Chief Executive Officer |
| Michael Kalb | Chief Financial Officer |
| Steven Miller | Chief Operating Officer |
| Mary Coleman | Head of Investor Relations |